AstraZeneca PLC (AZN)
| Market Cap | 262.55B |
| Revenue (ttm) | 56.50B |
| Net Income (ttm) | 8.30B |
| Shares Out | 1.55B |
| EPS (ttm) | 5.31 |
| PE Ratio | 16.03 |
| Forward PE | 17.53 |
| Dividend | $1.54 (1.80%) |
| Ex-Dividend Date | Aug 8, 2025 |
| Volume | 4,900,540 |
| Open | 84.58 |
| Previous Close | 84.51 |
| Day's Range | 84.30 - 85.17 |
| 52-Week Range | 61.24 - 86.57 |
| Beta | 0.17 |
| Analysts | Strong Buy |
| Price Target | n/a |
| Earnings Date | Nov 11, 2025 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial StatementsNews
AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to redefine cancer care with new data across its diverse, industry-leading portfolio and pipeline at the European Society for Medic...
Banquets and billions: How AstraZeneca sealed a US medicine deal with Trump
AstraZeneca CEO Pascal Soriot looked relaxed standing in the Oval Office on Friday as U.S. President Donald Trump unveiled a medicine deal that will lower drug prices for millions of Americans.
Trump announces drug-pricing deal with pharma giant
President Trump details a new drug-pricing deal with AstraZeneca, and Fox News political analyst Lisa Boothe reacts on 'The Evening Edit.'
Trump reaches deal with AstraZeneca to lower U.S. drug prices
The Trump administration and AstraZeneca announced Friday they have reached an agreement for the U.K.-based pharmaceutical giant to cut drug prices in the U.S. The deal with AstraZeneca follows a simi...
AstraZeneca Cuts Discounted Drug Pricing Deal With the White House. The Stock Is Rising.
AstraZeneca on Friday became the second big drugmaker after Pfizer to cut a pricing deal with the White House, announcing an agreement alongside President Donald Trump at a late afternoon press confer...
Pres. Trump announces deal with AstraZeneca to lower U.S. drug prices
CNBC's Bertha Coombs details the Trump administration and AstraZeneca's agreement for the U.K.-based pharmaceutical giant to cut drug prices in the United States.
TrumpRx makes more drug pricing moves and strikes a deal with AstraZeneca
Trump announces AstraZeneca deal for lower drug prices on TrumpRx.com platform. AstraZeneca, a UK-based firm, said it will offer discounts on its prescription drug catalog.
Trump says AstraZeneca to offer drugs to US at discounted prices
U.S. President Donald Trump announced an agreement with AstraZeneca on Friday where the drugmaker will offer its catalog of prescription drugs to the United States at a discounted price.
AstraZeneca to become latest drugmaker to strike deal with Trump. Its stock is down but outperforming the market.
AstraZeneca PLC looks poised to announce a deal with U.S. President Donald Trump that's focused on lowering drug prices, in a move that would see the British drugmaker follow in the footsteps of Pfize...
AstraZeneca is the latest major drugmaker to strike a deal with the Trump administration on lowering U.S. drug prices, according to a person familiar with the matter
The agreement follows last week's deal with Pfizer.
Trump reaches deal with AstraZeneca to lower U.S. drug prices, MSNBC reports
The Trump administration and AstraZeneca have reached an agreement for the U.K.-based pharmaceutical giant to cut drug prices in the U.S., MSNBC reported. President Donald Trump has already agreed to ...
Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly
Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump's administration to lower drug prices ...
AstraZeneca breaks ground at $4.5 billion Virginia plant as drugmakers court Trump
AstraZeneca broke ground on a new plant in Virginia on Thursday and said it would spend $4.5 billion on the facility as drugmakers look to respond to President Donald Trump's call for more medicines t...
AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announces that it will invest $4.5 billion in its new manufacturing facility in Virginia, a proposed increase of $500m to support the enhanced manu...
Turbine Launches Collaboration with AstraZeneca, Leveraging Turbine's Virtual Disease Models to Rationalize ADC Discovery
LONDON, UK and BUDAPEST, HUNGARY , Oct. 9, 2025 /PRNewswire/ -- Turbine, a leading company specializing in virtualizing biological experiments with AI, today announced a collaboration with AstraZeneca...
Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in a...
AstraZeneca's Baxdrostat meets main goal in high blood pressure study
AstraZeneca said on Tuesday its drug Baxdrostat met the main goal in a late-stage study in patients with treatment-resistant high blood pressure, or hypertension.
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...
AstraZeneca signs up to $555 million deal with US-based Algen to develop gene therapies
Algen Biotechnologies said on Monday it has agreed to grant AstraZeneca a license to develop gene therapies the U.S.-based biotech discovers using its artificial intelligence-driven platform, in a dea...
Algen Biotechnologies Announces Multi-Target Partnership to Advance AI-Powered Drug Discovery in Immunology with AstraZeneca
SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Algen Biotechnologies Announces Multi-Target Partnership to Advance AI-Powered Drug Discovery in Immunology with AstraZeneca.
AstraZeneca inks $555 million gene-editing technology deal with Algen, FT reports
AstraZeneca has signed a $555 million deal with a San Francisco-based biotech business Algen Biotechnologies, The Financial Times reported on Monday.
AstraZeneca's Datroway boosts survival in advanced breast cancer trial
AstraZeneca said on Monday its precision drug Datroway improved overall survival and progression free survival in patients with an advanced form of breast cancer versus chemotherapy in a trial when gi...
Pharmaceutical Stocks: Valuations And Pipelines Are Only Beginning To Be Appreciated
Drug stocks are poised to outperform in 2025, driven by conservative valuations and a research renaissance in key therapeutic areas. US healthcare spending growth and transformative GLP-1 therapies, e...
AstraZeneca shares leap with FDA set to review drug to treat breast cancer
AstraZeneca shares rallied on Wednesday after the U.K. giant and its Japanese partner said the Food and Drug Administration was reviewing one of its drugs to treat breast cancer.
CNBC's UK Exchange newsletter: AstraZeneca gets a shot on Wall Street
AstraZeneca is delisting its American Depositary Receipts from the Nasdaq, replacing them with a direct listing of ordinary shares on the New York Stock Exchange. At first blush, it confirms fears fir...